Before you decide to take those statins, please
When assessing CHD risk, cholesterol testing alone is not always enough.
The PLAC Test for lipid Activity is an FDA-cleared test that aids in predicting risk for CHD in patients with no prior history of cardiovascular events and provides useful prognostic information that was previously unavailable with traditional risk factors.
To check your PLAC test visit www.healthtestathome.com
It helps to make informed decisions about reducing future CHD events by measuring the amount of damage to the interior walls of blood vessels.
It Incorporates a validated and easy-to-use PLAC test that has a cut point of 225 nmol/min/mL to predict increased CHD risk.
The greater PLAC result, the greater the risk for fatal and nonfatal CHD events.
PLAC activity above 225 nmol/min/mL identifies patients at increased risk for CHD events, and therefore aids the decision to use statins or not.
Absolute risk for CHD events is 2.1 times greater with a positive PLAC Test.
One of the largest National Institutes of Health (NIH) studies ever undertaken, with over 30,000 patients enrolled across the United States has shown that a high PLAC result is a good indicator of future adverse CHD events. The Lp-PLA2 substudy examined 4,598 case-matched patients. A cut point of 225 nmol/min/mL was prospectively assigned based on prior studies and publications.
In a REGARDS multicenter substudy, high Lp-PLA2 activity was more closely associated with outcome than high low-density lipoprotein cholesterol (LDL) and low high-density lipoprotein cholesterol (HDL).
Tha only other 2 factors that were more closely associated with adverse CHD events were diabetes or smoking .
Patients with positive PLAC activity are at high risk for first-time myocardial infarction, cardiac revascularization, and cardiac death.
The cut point of 225 nmol/min/mL achieved statistical significance for each individual risk component.